Sheptulina, A.F.; Mamutova, E.M.; Elkina, A.Y.; Timofeev, Y.S.; Metelskaya, V.A.; Kiselev, A.R.; Drapkina, O.M.
Serum Irisin, Myostatin, and Myonectin Correlate with Metabolic Health Markers, Liver Disease Progression, and Blood Pressure in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease and Hypertension. Metabolites 2024, 14, 584.
https://doi.org/10.3390/metabo14110584
AMA Style
Sheptulina AF, Mamutova EM, Elkina AY, Timofeev YS, Metelskaya VA, Kiselev AR, Drapkina OM.
Serum Irisin, Myostatin, and Myonectin Correlate with Metabolic Health Markers, Liver Disease Progression, and Blood Pressure in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease and Hypertension. Metabolites. 2024; 14(11):584.
https://doi.org/10.3390/metabo14110584
Chicago/Turabian Style
Sheptulina, Anna F., Elvira M. Mamutova, Anastasia Yu. Elkina, Yuriy S. Timofeev, Victoria A. Metelskaya, Anton R. Kiselev, and Oxana M. Drapkina.
2024. "Serum Irisin, Myostatin, and Myonectin Correlate with Metabolic Health Markers, Liver Disease Progression, and Blood Pressure in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease and Hypertension" Metabolites 14, no. 11: 584.
https://doi.org/10.3390/metabo14110584
APA Style
Sheptulina, A. F., Mamutova, E. M., Elkina, A. Y., Timofeev, Y. S., Metelskaya, V. A., Kiselev, A. R., & Drapkina, O. M.
(2024). Serum Irisin, Myostatin, and Myonectin Correlate with Metabolic Health Markers, Liver Disease Progression, and Blood Pressure in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease and Hypertension. Metabolites, 14(11), 584.
https://doi.org/10.3390/metabo14110584
